NeoClinical™, the leading digital clinical trial recruitment agency for Australia, New Zealand and Asian markets todayofficially launched its latest recruitment product, Neo PayPerPatient click here.
Neo PayPerPatient has emerged from 6 months of beta testing, including regulatory compliance, and integration of some of the latest online consumer engagement software and tools. Neo PayPerPatient has already built powerful databases of people wanting more information about the latest clinical trials for conditions including gout, arthritis, Alzheimer’s, menopause, diabetes, prostate cancer and asthma.
Neo PayPerPatient is a risk share pay-as-you-go solution for new studies or current studies that are underperforming and need a boost to recruitment. Sponsors only pay a nominal fee for partially screened patients then a moderate fee for those that proceed to full enrolment. NeoClinical™ manages all the rest. NeoClinical™‘s advertising and PR expertise as well as the team’s considerable online and social media experience to deliver results for clients. NeoClinical™ study recruitment campaigns feature innovative and EC compliant advertising, public relations and online content marketing campaigns.
NeoClinical™ typically achieves referral conversion rates of 40-60% and recently achieved a 63% conversion rate for a New Zealand Study.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.